White Paper

The value of mRNA vaccines & therapeutics

Format: PDF file | Document type: White Paper | Promoted Content

This content is provided by Curia, and any views and opinions expressed do not necessarily reflect those of www.biopharma-reporter.com

The value of mRNA vaccines & therapeutics

The number of clinical trials featuring RNA-based drug products has increased dramatically since 2020. Infectious disease and cancer are the main targets (83%) for these clinical trials and, while some use antisense oligos (ASOs), small interfering RNA (siRNA) and other RNA modalities, the vast majority of these use mRNA. Given this interest, it is no surprise that the mRNA cancer vaccines and therapeutics market was estimated to be worth about $47 billion in 2021 and is projected to grow to $109 billion by 2028.

Related resources from Curia

Supplier info centre